[Bronchospasmolytic effect of reproterol as aerosol (author's transl)].
In an intraindividual double-blind study the effect of 1% (2.5 mg) and 2% (5 mg) reproterol aerosol was investigated in 30 patients with chronic obstructive bronchitis and asthma. Both solutions had a statistically highly significant bronchospasmolytic effect when airways resistance and specific conductance were measured. The effect was demonstrable immediately after termination of inhalation. Cardiac frequency and blood pressure remained unchanged. No subjective side effects were reported.
D000336:Aerosols; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D001991:Bronchitis / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009921:Metaproterenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013806:Theophylline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000336:Aerosols; D001993:Bronchodilator Agents; D004338:Drug Combinations; C014792:reproterol; D009921:Metaproterenol; D013806:Theophylline
Bronchospasmolytische Wirkung von Reproterol als Inhalationslösung.